Cardiomyopathy

In this Healio video exclusive, Jonathan H. Kim, MD, provides an overview of the recently published scientific statement on clinical considerations for participation of athletes with heart disease in competitive sports.

Recent changes to a heart transplant allocation policy improved waitlist outcomes for children born with heart defects and adults with cardiomyopathy, but not in children with cardiomyopathy or adults with heart defects, data show.

The American College of Cardiology recently issued an expert consensus document outlining a novel staging system and decision pathway for the diagnosis, treatment and longitudinal follow-up of patients with myocarditis.

Researchers found genetic differences in hereditary palmoplantar keratoderma subtypes, indicating that genetic testing may be a valuable tool in accurately diagnosing the disease, according to a study.

CHICAGO — Catheter ablation improved outcomes compared with antiarrhythmic drug therapy in patients with ventricular tachycardia and ischemic cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.

CHICAGO — A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin reduced transthyretin levels in patients with cardiac amyloidosis, researchers reported at the American Heart Association Scientific Sessions.

In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show.

Among patients with transthyretin amyloidosis with cardiomyopathy, vutrisiran, an RNA interference agent, reduced risk for death and recurrent CV events compared with placebo, according to the results of the HELIOS-B trial.

Alnylam Pharmaceuticals announced the positive top-line results of the phase 3 HELIOS-B trial of its investigational RNA interfering therapy vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy.